Celecoxib 200 mg BID for Trochanteric Bursitis
For trochanteric bursitis, use celecoxib 200 mg twice daily for 14 days, which is the evidence-based duration for acute inflammatory bursitis conditions. 1, 2
Dosing Rationale
The FDA-approved dosing for celecoxib in acute pain conditions specifies an initial dose of 400 mg, followed by 200 mg twice daily as needed 1. However, for inflammatory bursitis specifically, the evidence supports starting directly with 200 mg twice daily without the loading dose, as demonstrated in the shoulder tendinitis/bursitis trial 2.
The 200 mg BID regimen (rather than 100 mg BID) is appropriate for acute bursitis because:
- This dose showed significant pain reduction within 24-48 hours in acute inflammatory conditions 2
- The higher dose provides more robust anti-inflammatory effect needed for acute bursitis
- Treatment duration of 14 days was the protocol that demonstrated efficacy in the acute shoulder bursitis study, which is directly applicable to trochanteric bursitis 2
Treatment Duration
Limit treatment to 14 days initially, then reassess. The evidence from acute bursitis treatment shows maximal benefit by Day 14 2. If symptoms persist beyond 2 weeks, this suggests:
- Possible abductor tendinopathy rather than simple bursitis 3
- Need for corticosteroid injection (which may be more effective than prolonged NSAID use) 4
- Consider alternative diagnoses within greater trochanteric pain syndrome 3
Critical Safety Considerations
Use the lowest effective dose for the shortest duration due to cardiovascular risks 5, 1. Key precautions:
- Cardiovascular risk: Celecoxib increases MI risk (rate ratio 1.86 vs placebo), though the 2016 PRECISION trial showed it was noninferior to naproxen and ibuprofen at moderate doses 5, 6
- Avoid in high-risk cardiac patients or fully inform them of excess cardiovascular risk 5
- Blood pressure monitoring: Expect mean increase of 5 mm Hg 7
- GI protection: Consider PPI if patient has GI bleeding history, though celecoxib alone has lower GI risk than nonselective NSAIDs 7
- Renal function: Use caution with ACE inhibitors, beta blockers, or pre-existing renal disease 7
Hepatic Dosing Adjustment
Reduce dose by 50% in moderate hepatic impairment (Child-Pugh Class B); avoid entirely in severe hepatic impairment 1.
When to Escalate Beyond NSAIDs
If no improvement after 14 days of celecoxib:
- Proceed to corticosteroid injection (74% of trochanteric bursitis patients ultimately require this) 4
- Consider imaging to evaluate for abductor tendinopathy 3
- Physical therapy targeting hip abductor strengthening
- In refractory cases, consider PRP injection 8
Do not continue celecoxib beyond 2-4 weeks without clear benefit, as prolonged NSAID use increases cardiovascular and GI risks without additional therapeutic advantage in bursitis 5, 1.